Kevin Tang
CIK 1178579 · Chief Executive Officer · last filed 2026-08-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
HRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 210
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BOLD | 10%+ Owner | 2,840,635 | $2.41 | $6.85M | -$108.7K | 1 | 2026-08-28 |
| AUPH | Director | 12,229,500 | $17.04 | $208.39M | $49.81M | 4 | 2026-03-03 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 4,338,617 | $1.48 | $6.42M | $262.9K | 1 | 2023-05-15 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | 10,000 | $1.88 | $18.8K | $0 | 1 | 2023-05-05 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Director | 10,049,224 | $6.22 | $62.51M | $108.22M | 16 | 2022-01-14 |
| Odonate Therapeutics, Inc. (ODT) Delisted | Chief Executive Officer | 15,375,428 | $1.12 | $17.22M | $181.59M | 13 | 2020-12-23 |
| HRTX | Director | 5,806,751 | $0.30 | $1.75M | -$194.04M | 10 | 2019-12-23 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 0 | — | — | $21.77M | 8 | 2012-06-20 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2010-09-22 |
| VNDA | 10%+ Owner | 2,884,671 | $3.94 | $11.37M | -$3.12M | 3 | 2010-01-13 |
| HERON THERAPEUTICS, INC. /DE/ (APPA) Delisted | 10%+ Owner | 16,496 | — | — | $1.82M | 2 | 2008-12-22 |
| ARADIGM CORP (ARDM) Delisted | 10%+ Owner | 13,500 | — | — | $18.0K | 1 | 2008-10-15 |
| NEOSE TECHNOLOGIES INC (NTEC) Delisted | 10%+ Owner | 487,506 | $9.63 | $4.69M | $995.6K | 1 | 2008-09-22 |
Recent Filings · Page 4 of 8
78 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-08-20 | Odonate Therapeutics, Inc. (ODT) Delisted | Buy (P) | +198,740 | $3.87M | EDGAR |
| 2018-08-15 | Odonate Therapeutics, Inc. (ODT) Delisted | Buy (P) | +91,240 | $1.73M | EDGAR |
| 2018-03-19 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Buy (P) | +1,525,422 | $45.00M | EDGAR |
| 2017-12-20 | HRTX | Grant (A) | — | $0 | EDGAR |
| 2017-12-13 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-08 | Odonate Therapeutics, Inc. (ODT) Delisted | Buy (P) | +5,166,664 | $124.00M | EDGAR |
| 2017-01-23 | HRTX | Buy (P) | +7,377,048 | $90.00M | EDGAR |
| 2017-01-06 | LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-23 | HRTX | Grant (A) | — | $0 | EDGAR |
| 2016-06-20 | HRTX | Mixed | +3,019,083 | -$37 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.